{"log_id": 6301549281459767949, "direction": 0, "words_result_num": 43, "words_result": [{"probability": {"variance": 0.007916, "average": 0.918404, "min": 0.753408}, "location": {"width": 645, "top": 98, "height": 34, "left": 277}, "words": " Gemzar 200mg, lg PI cn-truth approved 20160421 (ref Smpc 2014060"}, {"probability": {"variance": 0.040313, "average": 0.574116, "min": 0.373335}, "location": {"width": 19, "top": 103, "height": 20, "left": 993}, "words": "a"}, {"probability": {"variance": 6.7e-05, "average": 0.995207, "min": 0.978804}, "location": {"width": 130, "top": 162, "height": 28, "left": 96}, "words": "肿瘤缓解率"}, {"probability": {"variance": 0.000337, "average": 0.963098, "min": 0.944735}, "location": {"width": 20, "top": 160, "height": 22, "left": 419}, "words": "26"}, {"probability": {"variance": 0.012996, "average": 0.918586, "min": 0.721376}, "location": {"width": 39, "top": 160, "height": 21, "left": 672}, "words": "0001"}, {"probability": {"variance": 0.016503, "average": 0.931709, "min": 0.444595}, "location": {"width": 803, "top": 184, "height": 37, "left": 210}, "words": "28天方案一吉西他滨联合顺铂吉西他滨1000mgm,第1.815天给药顺铂100mgm第1天给"}, {"probability": {"variance": 0.005428, "average": 0.969296, "min": 0.682411}, "location": {"width": 622, "top": 215, "height": 28, "left": 211}, "words": "药每28天为一周期。单药顺铂顺铂100mg/m2,第1天,每28天为一周期"}, {"probability": {"variance": 0.007106, "average": 0.965952, "min": 0.513338}, "location": {"width": 799, "top": 241, "height": 28, "left": 214}, "words": "21天方案一吉西他滨联合顺铂:吉西他滨1250mg/m2第1,8天顺铂100mg/m2第1天,每21"}, {"probability": {"variance": 0.016075, "average": 0.938927, "min": 0.466542}, "location": {"width": 816, "top": 268, "height": 25, "left": 199}, "words": "天为一周期:依托泊苷联合顺铂:顺铂100mg/m2,第1天给药;依托浪苷100mg/m2第1,2,3天静"}, {"probability": {"variance": 0.019749, "average": 0.943626, "min": 0.485992}, "location": {"width": 217, "top": 297, "height": 23, "left": 195}, "words": "脉给药,每21天为一周期"}, {"probability": {"variance": 3e-06, "average": 0.997789, "min": 0.994833}, "location": {"width": 155, "top": 322, "height": 25, "left": 207}, "words": "NA:资料未提供"}, {"probability": {"variance": 0.000143, "average": 0.993379, "min": 0.969501}, "location": {"width": 173, "top": 349, "height": 23, "left": 208}, "words": " Kamofsky行为状态"}, {"probability": {"variance": 0.008466, "average": 0.971367, "min": 0.505152}, "location": {"width": 807, "top": 372, "height": 27, "left": 211}, "words": "肿瘤缓解率的P值应用双侧 Fisher's精确检验计算两个百分比的差异;其他的P值应用 Log rank"}, {"probability": {"variance": 4.4e-05, "average": 0.997417, "min": 0.974121}, "location": {"width": 279, "top": 400, "height": 26, "left": 195}, "words": "检验计算至某事件发生率的差异"}, {"probability": {"variance": 5.4e-05, "average": 0.986594, "min": 0.97741}, "location": {"width": 77, "top": 483, "height": 29, "left": 198}, "words": "胰腺癌"}, {"probability": {"variance": 0.000252, "average": 0.995977, "min": 0.907707}, "location": {"width": 780, "top": 526, "height": 33, "left": 238}, "words": "两项临床研究对吉西他滨治疗局部晚期或转移性胰腺癌进行了评价。第一项"}, {"probability": {"variance": 0.007655, "average": 0.979001, "min": 0.503677}, "location": {"width": 816, "top": 574, "height": 32, "left": 197}, "words": "研究吉西他滨与5-FU对比治疗初治患者,第二项研究吉西他滨治疗既往应用过"}, {"probability": {"variance": 0.000317, "average": 0.993543, "min": 0.890377}, "location": {"width": 816, "top": 622, "height": 30, "left": 198}, "words": "5FU或包含5-FU的方案化疗的胰腺癌患者。两项研究中,第一周期给予吉西他"}, {"probability": {"variance": 0.008189, "average": 0.963939, "min": 0.554635}, "location": {"width": 820, "top": 668, "height": 32, "left": 195}, "words": "滨1000mg/m2,30分钟内静脉给药,每周一次,共用7周(或至因毒性不能耐受)然后"}, {"probability": {"variance": 0.011054, "average": 0.968393, "min": 0.537462}, "location": {"width": 654, "top": 715, "height": 32, "left": 195}, "words": "休息一周。随后治疗为每周给药一次,连用3周,每4周为一周期"}, {"probability": {"variance": 0.003968, "average": 0.982255, "min": 0.647251}, "location": {"width": 779, "top": 761, "height": 32, "left": 237}, "words": "这些研究的主要疗效指标是临床获益反应,主要体现在止痛药的消耗、疼痛强"}, {"probability": {"variance": 0.0006, "average": 0.990095, "min": 0.88588}, "location": {"width": 819, "top": 806, "height": 36, "left": 195}, "words": "度、行为状态和体重改变等临床因素的改善。该两项临床研究方案设计过程中对"}, {"probability": {"variance": 0.004291, "average": 0.976914, "min": 0.678457}, "location": {"width": 826, "top": 850, "height": 43, "left": 197}, "words": "预期的变量改善进行了定义。如果出现以下的一种情况,患者被认为只有临床获"}, {"probability": {"variance": 0, "average": 0.998251, "min": 0.998251}, "location": {"width": 26, "top": 912, "height": 25, "left": 197}, "words": "益"}, {"probability": {"variance": 0.001091, "average": 0.9887, "min": 0.84326}, "location": {"width": 749, "top": 951, "height": 32, "left": 266}, "words": "患者疼痛强度减轻50%以上(疼痛记忆评价卡片法)或止痛药的消耗或行"}, {"probability": {"variance": 0.003593, "average": 0.983544, "min": 0.670794}, "location": {"width": 747, "top": 996, "height": 34, "left": 270}, "words": "为状态( Karnofsky行为状态)评分改善20分或以上至小持续4周而其他"}, {"probability": {"variance": 0.000111, "average": 0.996084, "min": 0.941765}, "location": {"width": 727, "top": 1044, "height": 35, "left": 267}, "words": "指标无任何持续的恶化。持续的恶化定义为在最初的12周治疗过程中"}, {"probability": {"variance": 0.009097, "average": 0.96443, "min": 0.563802}, "location": {"width": 750, "top": 1093, "height": 32, "left": 270}, "words": "任何的疼痛强度或痛药消耗增加或行为状态评分降低达20分,持续4"}, {"probability": {"variance": 0, "average": 0.999945, "min": 0.999945}, "location": {"width": 27, "top": 1145, "height": 27, "left": 269}, "words": "周"}, {"probability": {"variance": 0.003919, "average": 0.722186, "min": 0.634086}, "location": {"width": 248, "top": 1131, "height": 63, "left": 385}, "words": "就来贸"}, {"probability": {"variance": 1e-06, "average": 0.998773, "min": 0.99763}, "location": {"width": 51, "top": 1192, "height": 28, "left": 196}, "words": "或者"}, {"probability": {"variance": 0, "average": 0.926748, "min": 0.926748}, "location": {"width": 112, "top": 1185, "height": 37, "left": 384}, "words": "限"}, {"probability": {"variance": 0.04433, "average": 0.869654, "min": 0.455637}, "location": {"width": 250, "top": 1143, "height": 84, "left": 775}, "words": "头有限公司"}, {"probability": {"variance": 0.02542, "average": 0.903337, "min": 0.433074}, "location": {"width": 818, "top": 1236, "height": 35, "left": 196}, "words": "i者所有上述的指标稳定脊显著的非体液潴留性的持续的体重增加e7"}, {"probability": {"variance": 1e-05, "average": 0.997363, "min": 0.991198}, "location": {"width": 103, "top": 1285, "height": 28, "left": 269}, "words": "持续>4周"}, {"probability": {"variance": 0.001068, "average": 0.987594, "min": 0.85658}, "location": {"width": 778, "top": 1331, "height": 29, "left": 239}, "words": "第一项多中心(来自美国和加拿大的17个中心)、前瞻、单盲、双组、随机"}, {"probability": {"variance": 0.003001, "average": 0.982035, "min": 0.673372}, "location": {"width": 819, "top": 1379, "height": 31, "left": 196}, "words": "临床研究中,对比了吉西他滨和5-FU治疗既往未经过化疗的局部晚期或转移性"}, {"probability": {"variance": 0.002045, "average": 0.979138, "min": 0.790118}, "location": {"width": 822, "top": 1425, "height": 32, "left": 196}, "words": "胰腺癌。5-FU,每周一次,每次600mg/m2,30分钟静脉给药。结果见表5。吉"}, {"probability": {"variance": 0.002223, "average": 0.977439, "min": 0.80865}, "location": {"width": 820, "top": 1473, "height": 31, "left": 197}, "words": "西他滨治疗组较5FU组患者的临床缓解率、生存期和疾病进展时间有统计学意"}, {"probability": {"variance": 0.00923, "average": 0.967817, "min": 0.544756}, "location": {"width": 817, "top": 1520, "height": 30, "left": 200}, "words": "义的显著增加。 kaplan-meier生存曲线见图4。两组都没有观察到明确的肿瘤客"}, {"probability": {"variance": 0, "average": 0.75701, "min": 0.75701}, "location": {"width": 127, "top": 1558, "height": 37, "left": 689}, "words": "1"}, {"probability": {"variance": 0.034571, "average": 0.84484, "min": 0.542414}, "location": {"width": 228, "top": 1600, "height": 42, "left": 649}, "words": "礼来贸易"}, {"probability": {"variance": 0.048754, "average": 0.8577, "min": 0.413603}, "location": {"width": 235, "top": 1636, "height": 38, "left": 647}, "words": "有有限公司"}], "language": 3}